HTG Launches Targeted Therapy Projects with Daiichi Sankyo, Centre Léon Bérard
HTG in the news with ClinicalOMICs: HTG LAUNCHES TARGETED THERAPY PROJECTS WITH DAIICHI SANKYO, CENTRE LÉON BÉRARD
News & Events
HTG EdgeSeq miRNA Whole Transcriptome Assay Performance Using Samples and Methods from the microRNA Quality Control (miRQC) Study
Join us Wednesday, April 12, 2017 for a Nature.com Webcast.
Join HTG on April 12 for this informative webinar and learn about the objectives and strategy for genomic platform comparison studies described by the MAQC consortium.
Global Congress on Molecular Pathology (AMP Global)
Join us Monday, April 3, 2017 through Wednesday, April 5, 2017 in Berlin, Germany.
HTG will be at the Global Congress on Molecular Pathology (AMP Global) 2017 meeting. Learn how our collaborators are innovating next-generation pathology with the NGS-based HTG EdgeSeq system and assays.
American Association for Cancer Research (AACR)
Join us April 1, 2017 through April 5, 2017 in Washington, DC.
HTG will be at the 2017 AACR Annual Meeting. Stop by to learn more about our NGS-based sequencing assays that are automated on the HTG EdgeSeq system.
HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN GeneReader NGS System
TUCSON, Ariz., March 23, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology has been successfully adapted for use with the QIAGEN GeneReader NGS System based on the results of initial technical feasibility tests. Results from samples tested with the HTG EdgeSeq DLBCL Cell of Origin Assay gene panel adapted for detection with the GeneReader NGS System showed strong correlation (r = 0.98) to data previously generated on the MiSeq sequencer.
HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2016 Results
TUCSON, Ariz., March 23, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the fourth quarter and year ended December 31, 2016.
HTG Molecular Diagnostics Obtains CE Mark for its HTG EdgeSeq ALKPlus Assay EU
TUCSON, Ariz., March 22, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has obtained CE marking in the European Union for its HTG EdgeSeq ALKPlus Assay EU.
The HTG EdgeSeq ALKPlus Assay EU is an in vitro diagnostic assay intended to measure and analyze mRNA ALK gene rearrangements in formalin-fixed, paraffin-embedded lung tumor specimens from patients previously diagnosed with non-small cell lung cancer (NSCLC). The assay may be used to aid in the identification of patients eligible for treatment with ALK-targeted therapeutics, such as crizotinib, and is automated on the HTG EdgeSeq system using a next-generation sequencer for detection.
HTG Molecular Diagnostics to Hold 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 23, 2017
TUCSON, Ariz., March 21, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2016 fourth quarter and full year financial results after market close on Thursday, March 23, 2017. Company management will host an investment-community conference call beginning at 5:00pm Eastern Time on Thursday, March 23 to discuss these results and answer questions.
HTG Molecular Diagnostics’ & QIAGEN Scientific Symposium
This no-fee Symposium brings together key molecular and pharma professionals for the opportunity to network, discuss noteworthy and trending topics and exchange information in the fields of immuno-oncology and companion diagnostics.
HTG Molecular Diagnostics’ Scientific Symposium
Join us Monday, March 20, 2017 through Tuesday March 21, 2017 in Paris, France.
This no-fee Symposium brings together key molecular and pharma professionals for the opportunity to network, discuss noteworthy and trending topics and exchange information in the fields of immuno-oncology and companion diagnostics.
HTG Molecular Diagnostics Appoints New Chair of the Board of Directors
TUCSON, Ariz., March 07, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that Ann F. Hanham, Ph.D., a director since August 2016, has been appointed to the Chair of the company’s board of directors.
HTG Molecular Diagnostics Unveils New Direct-Target Sequencing Chemistry to Launch in First Quarter 2017
TUCSON, Ariz., Feb. 27, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM)(“HTG”), a provider of instruments, reagents and services for molecular profiling applications announced that its new direct-target sequencing chemistry will be available in the company’s VERI/O laboratory as a service offering beginning in the first quarter of 2017. The new chemistry is designed for direct sequencing of specified DNA and, in the future, RNA targets with the same high sensitivity and specificity as the company’s current HTG EdgeSeq chemistry applications. The initial panel planned for the VERI/O laboratory will detect common mutations in the EGFR, KRAS and BRAF genes for retrospective research studies especially from small and difficult samples, such as formalin-fixed, paraffin-embedded (FFPE) tissue.
Page last updated March 20, 2023